Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $796.82
MGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that study...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3...
Eisai Co., Ltd. (Tokyo, TSE: 4523) (?Eisai?) and MGI PHARMA, INC. (NASDAQ: MOGN) (?MGI PHARMA?) announced today that the...
NEW YORK, Jan. 16 /PRNewswire/ -- HMS Holdings Corp. (NASDAQ:HMSY) will replace MGI PHARMA Inc. (NASDAQ:MOGN) in the S&P SmallCap 600 after the...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment...
SCHEDULE 13G Amendment No. 3 MGI Pharma Inc Common Stock Cusip #552880106 Cusip #552880106 Item 1: Reporting Person - FMR LLC Item 4:...
OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden...
On December 26, 2007, MGI PHARMA, INC. issued a Notice of Conversion Right to holders of its Senior Subordinated Convertible...
QuickLinks -- Click here to rapidly navigate through this document SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO...
MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, and its partner HELSINN...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to...
MGI PHARMA, INC. (NASDAQ:MOGN) (the ?Company? or ?MGI PHARMA?), today announced that the Company?s Senior Subordinated...
QuickLinks -- Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.